Dat T Tran1, Robert C Welsh2, Arto Ohinmaa3, Nguyen X Thanh3, Padma Kaul4. 1. School of Public Health, University of Alberta, Edmonton, Alberta, Canada; Canadian VIGOUR Centre, University of Alberta, Edmonton, Alberta, Canada. Electronic address: dttran@ualberta.ca. 2. Canadian VIGOUR Centre, University of Alberta, Edmonton, Alberta, Canada; Department of Medicine, University of Alberta, Edmonton, Alberta, Canada; Mazankowski Alberta Heart Institute, University of Alberta Hospital, Edmonton, Canada. 3. School of Public Health, University of Alberta, Edmonton, Alberta, Canada; Institute of Health Economics, Edmonton, Alberta, Canada. 4. Canadian VIGOUR Centre, University of Alberta, Edmonton, Alberta, Canada; Department of Medicine, University of Alberta, Edmonton, Alberta, Canada.
Abstract
BACKGROUND: Little is known about the resource use and cost burden of acute myocardial infarction (AMI) beyond the index event. We examined resource use and care costs during the first and each subsequent year, among patients with incident AMI. METHODS: Patients aged ≥18 years who were admitted with incident AMI at emergency departments or hospitals in Alberta, Canada, between April 2004 and March 2014 were included. Incident cases were defined as those without an AMI hospitalization in the previous 10 years. Inpatient, outpatient, practitioner claims, drug claims, and vital statistics were linked and follow-up data were available until March 2016. Resource use and care costs per patient for each year after the AMI were calculated. RESULTS: The analysis included 41,210 patients with incident AMI (non-ST-segment elevation myocardial infarction [NSTEMI] = 50.8%, ST-segment elevation myocardial infarction = 36.8%, and undefined myocardial infarction [MI] = 12.5%). Resource use and care costs were highest during the first year. Compared with other MI groups, patients with ST-segment elevation myocardial infarction had more frequent outpatient visits (mean 1.64 vs 0.99 [NSTEMI] and 0.87 [undefined MI] visits) but spent fewer days in hospital (mean 7.72 vs 9.23 [NSTEMI] and 8.5 [undefined MI] days) during the first year. AMI costs were $19,842 during the first year and $845 per year for the next 5 years. Hospitalization costs accounted for the majority of costs during the first year (81.1%), whereas drug costs did for the next 5 years (62.1%). CONCLUSIONS: The long-term annual cost burden of AMI is modest compared with care costs during the first year. Although hospitalization dominates first year costs, pharmaceuticals do so in the long term.
BACKGROUND: Little is known about the resource use and cost burden of acute myocardial infarction (AMI) beyond the index event. We examined resource use and care costs during the first and each subsequent year, among patients with incident AMI. METHODS:Patients aged ≥18 years who were admitted with incident AMI at emergency departments or hospitals in Alberta, Canada, between April 2004 and March 2014 were included. Incident cases were defined as those without an AMI hospitalization in the previous 10 years. Inpatient, outpatient, practitioner claims, drug claims, and vital statistics were linked and follow-up data were available until March 2016. Resource use and care costs per patient for each year after the AMI were calculated. RESULTS: The analysis included 41,210 patients with incident AMI (non-ST-segment elevation myocardial infarction [NSTEMI] = 50.8%, ST-segment elevation myocardial infarction = 36.8%, and undefined myocardial infarction [MI] = 12.5%). Resource use and care costs were highest during the first year. Compared with other MI groups, patients with ST-segment elevation myocardial infarction had more frequent outpatient visits (mean 1.64 vs 0.99 [NSTEMI] and 0.87 [undefined MI] visits) but spent fewer days in hospital (mean 7.72 vs 9.23 [NSTEMI] and 8.5 [undefined MI] days) during the first year. AMI costs were $19,842 during the first year and $845 per year for the next 5 years. Hospitalization costs accounted for the majority of costs during the first year (81.1%), whereas drug costs did for the next 5 years (62.1%). CONCLUSIONS: The long-term annual cost burden of AMI is modest compared with care costs during the first year. Although hospitalization dominates first year costs, pharmaceuticals do so in the long term.
Authors: Hedi Katre Kriit; Jennifer Stewart Williams; Lars Lindholm; Bertil Forsberg; Johan Nilsson Sommar Journal: BMJ Open Date: 2019-09-17 Impact factor: 2.692
Authors: Jun-Hui Wu; Yao Wu; Zi-Jing Wang; Yi-Qun Wu; Tao Wu; Meng-Ying Wang; Xiao-Wen Wang; Si-Yue Wang; Jia-Ting Wang; Huan Yu; Yong-Hua Hu Journal: Int J Environ Res Public Health Date: 2021-04-01 Impact factor: 3.390
Authors: My Hanh Bui; Quynh Long Khuong; Phuoc Thang Dao; Cao Phuong Duy Le; The Anh Nguyen; Binh Giang Tran; Duc Hung Duong; Tuan Duc Duong; Tien Hung Tran; Hoang Ha Pham; Xuan Thanh Dao; Quang Cuong Le Journal: Front Public Health Date: 2021-12-10
Authors: Michelle Samuel; Jean-Claude Tardif; Paul Khairy; François Roubille; David D Waters; Jean C Grégoire; Fausto J Pinto; Aldo P Maggioni; Rafael Diaz; Colin Berry; Wolfgang Koenig; Petr Ostadal; Jose Lopez-Sendon; Habib Gamra; Ghassan S Kiwan; Marie-Pierre Dubé; Mylène Provencher; Andreas Orfanos; Lucie Blondeau; Simon Kouz; Philippe L L'Allier; Reda Ibrahim; Nadia Bouabdallaoui; Dominic Mitchell; Marie-Claude Guertin; Jacques Lelorier Journal: Eur Heart J Qual Care Clin Outcomes Date: 2021-09-16